Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
targeted cancer drugs
Pharma
In landmark for Korean biotech, Elevar wins FDA nod for Lyrfigtu
Lyrfigtu was designed with increased selectivity for FGFR2, while sparing other proteins of the FGFR family, to minimize toxicities.
Angus Liu
Sep 24, 2026 11:25am
Pfizer scores again in HER2-positive breast cancer
Oct 14, 2025 12:33pm
FDA clears Bristol Myers cancer drug from Turning Point buy
Nov 16, 2023 11:10am
Golf pro Day hosts AZ video series to push biomarker testing
Apr 15, 2022 7:48am
Takeda beefs up digital content team, AI amid Exkivity launch
Apr 6, 2022 1:54pm
